From Our Partners
Wednesday, June 22, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Policy + Initiatives

NIAID Selects New Director of the Vaccine Research Center

by Global Biodefense Staff
October 18, 2013

John R. Mascola, M.D., an internationally recognized expert on HIV vaccine development, has been named the new director of the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

In this role, Dr. Mascola will lead a comprehensive research program aimed at the design, development and testing of candidate vaccines against HIV/AIDS, influenza and other globally important infectious diseases. He will also serve as chief of the VRC virology laboratory.

“John Mascola is a visionary leader who brings a wealth of talents as a basic scientist, clinician, clinical trialist and administrator to the helm of the Vaccine Research Center,” said NIAID Director Anthony S. Fauci, M.D. “In particular, his exemplary work on elucidating the protective role of antibodies against HIV has greatly influenced current vaccine design efforts.  I am confident that Dr. Mascola will continue and even accelerate our momentum toward the development of novel, effective vaccines against infectious diseases.”

Dr. Mascola previously served as acting director and deputy director of the VRC. He also led the center’s core virology laboratory. Among his many accomplishments, he and his colleagues were the first to demonstrate that the infusion of neutralizing antibodies could protect against mucosal HIV exposure in monkeys. Dr. Mascola and his colleagues also have made advances in the study of human antibody responses to natural HIV infection, including the isolation in 2010 of two antibodies from the blood of an HIV-infected person that can neutralize more than 90 percent of known HIV strains. VRC researchers continue to study these and other potent neutralizing antibodies in hopes of developing an effective HIV vaccine.

“John is an innovative scientist and a great choice to lead the Vaccine Research Center,” said NIH Director Francis S. Collins, M.D., Ph.D. “His expertise in vaccine development will undoubtedly help advance important research programs against infectious diseases such as HIV/AIDS and influenza.”

Dr. Mascola graduated magna cum laude from Tufts University, Boston, and earned his medical degree from the Georgetown University School of Medicine, Washington D.C. He completed a residency in internal medicine at the San Diego Naval Medical Center and a fellowship in infectious diseases at the National Naval Medical Center, Bethesda, Md., followed by a fellowship in retroviral diseases at the Walter Reed Army Institute of Research, Silver Spring, Md. Dr. Mascola is a fellow of the American College of Physicians and a member of the Infectious Diseases Society of America. He has been elected to the American Society of Clinical Investigation and the Association of American Physicians.

“The Vaccine Research Center is a unique, state-of-the-art facility, with a complement of extraordinarily dedicated and talented scientists and staff.   I am honored to be selected as its new director,” said Dr. Mascola. “I look forward to expanding our basic research on immune responses to HIV and other infections and applying this knowledge to the development of strategies to prevent and treat human diseases.”

Dr. Mascola replaces Gary J. Nabel, M.D., Ph.D., who in November 2012 left the position of VRC Director to become the deputy to the president for Global Research and Development, senior vice president and chief scientific officer at the pharmaceutical company Sanofi.

Source: National Institutes of Health

From Our Partners
Tags: LeadershipVaccines

Related Posts

Will Omicron Be More Contagious Than Delta?
Biosecurity

U.S. Government to Conduct Sweeping Review of Biosecurity Policy Frameworks

February 28, 2022
New GAO Report Addresses Nation’s Biodefense Programmatic Challenges
Policy + Initiatives

New GAO Report Addresses Nation’s Biodefense Programmatic Challenges

February 17, 2022
Biodefense Funding and Legislation
Policy + Initiatives

Medical Countermeasures Surge Capacity Act of 2022 Introduced in Senate

February 7, 2022
BSL-4 Laboratory at USAMRIID
Biosecurity

Submit Comments on Draft Policy Statement for BSL-4 Laboratory Verification

February 6, 2022
Load More

Latest News

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022
Biodefense Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Biodefense Headlines – 16 June 2022

Biodefense Headlines – 16 June 2022

June 16, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC